ATE536372T1 - Verfahren zur hoher expression der aktiven form von lymphotoxin-beta-rezeptor-immunglobulin fusionsproteinen, und deren reinigung - Google Patents

Verfahren zur hoher expression der aktiven form von lymphotoxin-beta-rezeptor-immunglobulin fusionsproteinen, und deren reinigung

Info

Publication number
ATE536372T1
ATE536372T1 AT99967350T AT99967350T ATE536372T1 AT E536372 T1 ATE536372 T1 AT E536372T1 AT 99967350 T AT99967350 T AT 99967350T AT 99967350 T AT99967350 T AT 99967350T AT E536372 T1 ATE536372 T1 AT E536372T1
Authority
AT
Austria
Prior art keywords
purification
lymphotoxin
immunolobulin
fusion proteins
active form
Prior art date
Application number
AT99967350T
Other languages
English (en)
Inventor
Jeffrey Browning
Konrad Miatkowski
Werner Meier
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22345666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE536372(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE536372T1 publication Critical patent/ATE536372T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT99967350T 1998-12-17 1999-12-16 Verfahren zur hoher expression der aktiven form von lymphotoxin-beta-rezeptor-immunglobulin fusionsproteinen, und deren reinigung ATE536372T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11275298P 1998-12-17 1998-12-17
PCT/US1999/029873 WO2000036092A2 (en) 1998-12-17 1999-12-16 METHOD FOR THE HIGH LEVEL EXPRESSION OF ACTIVE LYMPHOTOXIN-β RECEPTOR IMMUNOGLOBULIN CHIMERIC PROTEINS AND THEIR PURIFICATION

Publications (1)

Publication Number Publication Date
ATE536372T1 true ATE536372T1 (de) 2011-12-15

Family

ID=22345666

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99967350T ATE536372T1 (de) 1998-12-17 1999-12-16 Verfahren zur hoher expression der aktiven form von lymphotoxin-beta-rezeptor-immunglobulin fusionsproteinen, und deren reinigung

Country Status (27)

Country Link
US (3) US7585946B2 (de)
EP (3) EP3006563A1 (de)
JP (4) JP4878676B2 (de)
KR (3) KR100732934B1 (de)
CN (2) CN101289512A (de)
AT (1) ATE536372T1 (de)
AU (2) AU777232B2 (de)
BR (1) BR9916325B1 (de)
CA (1) CA2354539A1 (de)
CY (1) CY1117003T1 (de)
CZ (1) CZ20012156A3 (de)
DK (2) DK2374872T4 (de)
EA (1) EA005270B1 (de)
EE (1) EE200100324A (de)
ES (1) ES2554482T5 (de)
HK (1) HK1223398A1 (de)
HU (1) HUP0200064A2 (de)
IL (3) IL143670A0 (de)
IS (1) IS5959A (de)
NO (1) NO20012991L (de)
NZ (3) NZ529276A (de)
PT (1) PT2374872E (de)
SG (1) SG123531A1 (de)
SI (1) SI2374872T2 (de)
SK (1) SK8552001A3 (de)
TR (2) TR200504220T2 (de)
WO (1) WO2000036092A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
CZ20011272A3 (cs) * 1998-10-09 2001-09-12 Biogen, Inc. Použití činidla, které blokuje vazbu lymfotoxinu-beta na jeho receptor, pro výrobu protivirového léku
CA2407426A1 (en) 2000-04-28 2001-11-08 Planet Biotechnology, Inc. Immunoadhesin for the prevention of rhinovirus infection
US20020168367A1 (en) * 2000-04-28 2002-11-14 Planet Biotechnology Incorporated Novel immunoadhesins for treating and preventing viral and bacterial diseases
US6919183B2 (en) * 2001-01-16 2005-07-19 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
MXPA05006522A (es) 2002-12-23 2006-02-17 Bristol Myers Squibb Co Mejora en la calidad de producto en procesos de cultivo en celulas de mamiferos para la produccion de proteina.
MXPA05006523A (es) 2002-12-23 2005-08-26 Squibb Bristol Myers Co Procesos de cultivo de celulas de mamiferos para la produccion de proteinas.
WO2005024012A1 (en) * 2003-09-11 2005-03-17 Novozymes A/S Increased expression of a modified polypeptide
US20070099266A1 (en) * 2003-12-23 2007-05-03 Applied Research Systems Ars Holding N.V. Process for the production of tumor necrosis factor-binding proteins
WO2007115230A2 (en) * 2006-03-30 2007-10-11 University Of Medicine And Dentistry Of New Jersey A strategy for homo- or hetero-dimerization of various proteins in solutions and in cells
UA94484C2 (uk) 2006-10-12 2011-05-10 Дженентек, Інк. Антитіла до лімфотоксину-альфа
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
CN101600450A (zh) * 2006-10-20 2009-12-09 比奥根艾迪克Ma公司 利用可溶性淋巴毒素β受体的脱髓鞘病的治疗
CA2680792A1 (en) * 2007-03-15 2008-09-18 Biogen Idec Ma Inc. Treatment of autoimmune disorders
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
BRPI0908270A2 (pt) * 2008-02-29 2019-09-10 Biogen Idec Inc proteínas de fusão de imunoglobulinas purificadas e método para a sua purificação
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
PL2563906T3 (pl) 2010-04-26 2018-04-30 Novartis Ag Sposób hodowli komórek cho
US20140128577A1 (en) * 2011-06-24 2014-05-08 Dr. Reddy's Laboratories Limited Purification of chimeric protein
KR101454316B1 (ko) 2011-08-17 2014-10-27 한화케미칼 주식회사 활성형 ＴＮＦＲ-Ｆｃ 융합 단백질을 제조하는 방법
JP2015531244A (ja) 2012-10-15 2015-11-02 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ タンパク質を製造するための哺乳動物細胞培養方法
TW202423993A (zh) 2012-11-14 2024-06-16 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
KR102669985B1 (ko) 2015-06-30 2024-05-29 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트 Btla 융합 단백질 작용제 및 이의 용도
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
CN105400721A (zh) * 2015-12-11 2016-03-16 湖南农业大学 一种快速筛选具有抗菌活性芽孢杆菌的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2906096A (en) 1953-12-14 1959-09-29 Pacific Ind Mfg Co Precision control system for press brakes or the like
JP2810744B2 (ja) 1989-07-04 1998-10-15 ノボ ノルディスク アクティーゼルスカブ Ｆ▲ｖｉｉｉ▼活性を有する蛋白質および／またはｆ▲ｖｉｉｉ▼誘導体の製造法
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US7030080B2 (en) * 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
JPH06501456A (ja) * 1990-06-27 1994-02-17 バイオジェン，インコーポレイテッド 表面複合リンホトキシン
US5670149A (en) * 1990-06-27 1997-09-23 Biogen, Inc. Lymphotoxin-β, Lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
NZ260103A (en) * 1990-11-30 1996-10-28 Bio Technology General Corp Somatotropin with alterations in the alpha-helix-1 region
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5643570A (en) * 1992-05-19 1997-07-01 Xoma Corporation BPI-immunoglobulin fusion proteins
AU670125B2 (en) * 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
WO1994006478A1 (en) 1992-09-22 1994-03-31 Medin Corporation A system for securing medical tools for sterilization
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
US5691196A (en) * 1992-12-31 1997-11-25 American Cyanamid Company Recombinant nucleic acid containing a response element
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5726039A (en) * 1994-07-21 1998-03-10 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Vectors and transformed host cells for recombinant protein production at reduced temperatures
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
EP0910413A2 (de) 1996-05-08 1999-04-28 F. Hoffmann-La Roche Ag Behandlung von asthma mit tnfr-ig
US6040560A (en) * 1996-10-22 2000-03-21 Philip Morris Incorporated Power controller and method of operating an electrical smoking system
US7255854B1 (en) * 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
KR100584704B1 (ko) * 1996-10-25 2006-05-30 바이오겐 아이덱 엠에이 인코포레이티드 면역 질환을 치료하기 위한 치료제로서의 가용성 림포톡신-베타 수용체, 항림포톡신 수용체 항체 및 항림포톡신 리간드 항체
CA2270913C (en) 1996-10-30 2011-05-24 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like 2
WO1998025967A1 (en) * 1996-12-12 1998-06-18 Genentech, Inc. Hvem polypeptides and uses thereof
US6221608B1 (en) * 1997-01-22 2001-04-24 Ortho Pharmaceutical Corporation Methods for identifying erythropoietin receptor binding protein
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
CA2325022A1 (en) * 1998-04-16 1999-10-21 Genentech, Inc. Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence
DE69929198T2 (de) 1998-05-29 2006-08-10 Genentech, Inc., South San Francisco Zellkulturverfahren für die produktion von glycoproteinen
CZ20011272A3 (cs) * 1998-10-09 2001-09-12 Biogen, Inc. Použití činidla, které blokuje vazbu lymfotoxinu-beta na jeho receptor, pro výrobu protivirového léku
US7294481B1 (en) * 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US9086881B2 (en) 2012-06-29 2015-07-21 Intel Corporation Mechanism for facilitating write tracking for following data eye movements across changing thermal conditions in memory systems

Also Published As

Publication number Publication date
CZ20012156A3 (cs) 2001-09-12
CN100387708C (zh) 2008-05-14
US20020039580A1 (en) 2002-04-04
EP2374872A2 (de) 2011-10-12
ES2554482T5 (es) 2019-07-18
NZ529276A (en) 2005-03-24
EP2374872B2 (de) 2019-02-20
JP2014239697A (ja) 2014-12-25
EE200100324A (et) 2002-10-15
PL348816A1 (en) 2002-06-17
PT2374872E (pt) 2015-12-09
JP2013116118A (ja) 2013-06-13
WO2000036092A9 (en) 2002-08-22
KR20020013482A (ko) 2002-02-20
IL205698A (en) 2015-11-30
IL143670A0 (en) 2002-04-21
NO20012991D0 (no) 2001-06-15
CN101289512A (zh) 2008-10-22
AU2005200042B2 (en) 2008-05-01
HK1038244A1 (en) 2002-03-08
TR200101703T2 (tr) 2002-05-21
EP1141248B1 (de) 2011-12-07
US8709759B2 (en) 2014-04-29
WO2000036092A2 (en) 2000-06-22
NZ538599A (en) 2007-11-30
DK2374872T4 (en) 2019-04-23
AU2005200042A1 (en) 2005-02-03
NO20012991L (no) 2001-08-17
SI2374872T1 (sl) 2016-03-31
DK1141248T3 (da) 2012-03-12
US8283138B2 (en) 2012-10-09
US20130196376A1 (en) 2013-08-01
KR100732934B1 (ko) 2007-06-29
BR9916325A (pt) 2001-10-02
EP3006563A1 (de) 2016-04-13
US7585946B2 (en) 2009-09-08
IS5959A (is) 2001-05-31
JP2010158252A (ja) 2010-07-22
DK2374872T3 (en) 2015-12-14
EA005270B1 (ru) 2004-12-30
IL229738A0 (en) 2014-01-30
AU2364400A (en) 2000-07-03
KR20070091227A (ko) 2007-09-07
JP2003517277A (ja) 2003-05-27
HUP0200064A2 (en) 2002-05-29
CN1333819A (zh) 2002-01-30
SI2374872T2 (sl) 2019-05-31
JP5777171B2 (ja) 2015-09-09
KR20060084860A (ko) 2006-07-25
SG123531A1 (en) 2006-07-26
WO2000036092A3 (en) 2000-11-23
EA200100670A1 (ru) 2001-12-24
SK8552001A3 (en) 2001-12-03
AU777232B2 (en) 2004-10-07
ES2554482T3 (es) 2015-12-21
JP4878676B2 (ja) 2012-02-15
EP2374872A3 (de) 2011-10-19
US20100136625A1 (en) 2010-06-03
HK1223398A1 (en) 2017-07-28
EP1141248A2 (de) 2001-10-10
CY1117003T1 (el) 2017-04-05
EP2374872B1 (de) 2015-11-25
CA2354539A1 (en) 2000-06-22
BR9916325B1 (pt) 2011-06-28
NZ549623A (en) 2008-05-30
TR200504220T2 (tr) 2007-04-24

Similar Documents

Publication Publication Date Title
ATE536372T1 (de) Verfahren zur hoher expression der aktiven form von lymphotoxin-beta-rezeptor-immunglobulin fusionsproteinen, und deren reinigung
DE69633563D1 (de) Neues verfahren zur gewinnung und reinigung von fusionsproteinen
DE60040259D1 (de) Knotensteuerungsvorrichtung, Knotenvorrichtung und Verfahren zur Einstellung von optischen Pfaden
ATE318146T1 (de) Verfahren zur aufkonzentrierung von antikörperlösungen
DE69942588D1 (de) Verfahren zur reduktion von emittiertem kohlendioxid
DE69707849D1 (de) Verfahren zur reinigung von 1,4-butandiol
ATE454621T1 (de) Verfahren für hochempfindliche hochgeschwindigkeits-kapillar-elektrophorese
DE69425115D1 (de) Katalytische Zusammensetzung und Verfahren zur Oxychlorierung von Ethylen unter Verwendung derselben
DE59702864D1 (de) Verfahren und anordnung zur automatischen optischen qualitätskontrolle von flachen, ebenen produkten
ATE397969T1 (de) Katalysator zur behandlung von schadstoff- enhaltenden gasen unter vorbeugung von kapillarer kondensation
ATE220558T1 (de) Verbessertes verfahren zur stabilisierung von proteinen
DE59913665D1 (de) Verfahren zur katalytischen herstellung von substituierten bipyridylderivaten
DE69816516D1 (de) Laservorrichtung und Verfahren für Laseremission unter Verwendung desselben
DE69534551D1 (de) Neue methode zum auffindenund bewerten biologisch aktiver moleküle
DE59808384D1 (de) Verfahren zur auswertung von fehlern von textilen flächengebilden
DE60021960D1 (de) Verfahren zur Kompensation von Neigung und/oder Defokussierung, und Vorrichtung für dasselbige
ATE223491T1 (de) Verfahren zur reinigung von biomolekül- oder proteinkomplexen
DE69836075D1 (de) Verfahren zur spaltung von fusionproteinen
DE60032077D1 (de) Verfahren zur dehalogenierung von kohlenwasserstoffhaltigen kohlenstoff-kohlenstoff doppelbindungen
ATE232685T1 (de) Verfahren und zusammensetzungen zur bekämpfung von biologischer verschmutzung unter verwendung von sulfaminsäuren
DE69738323D1 (de) Verfahren zur verringerung der abbaubarkeit von futterprotein
ATE261579T1 (de) Chromatographiematerial und verfahren unter verwendung desselben
DE3575905D1 (de) Verfahren zur reinigung von kohlendioxyd.
DE59803134D1 (de) Verfahren zur bekämpfung von schadpilzen
DE69800114D1 (de) Verfahren zur Hydrierung von Cyanopropanaldehyden enthaltend Cyanopropionaldehydacetalen